Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ROSG's 30-Y Financials

Financials (Next Earnings Date: 0)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with ROSG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Rosetta Genomics Ltd does not have enough historical financial data to display Peter Lynch Chart.

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research  
Compare:XCNQ:RLSC, NGM:LIFE B, TSXV:IDL, BOM:526546, XCNQ:BUX, OTCPK:TEAR, BOM:526301, OTCPK:ABMC, ASX:CTE, WAR:REV, TSXV:MBI, OTCPK:JFIL, OTCPK:MEDD, OTCPK:EXDI, OTCPK:ETAH, OTCPK:MDIT, BOM:526504, OTCPK:BZYR, WAR:IGN, OTCPK:DCTH » details
Traded in other countries:RQ1.Germany,
Headquarter Location:Israel
Rosetta Genomics Ltd is engaged in the development and commercialization of new diagnostic products based on a recently discovered group of genes known as microRNAs. MicroRNAs are naturally expressed, or produced, using instructions encoded in DNA.

Rosetta Genomics Ltd is an Israel based genomic diagnostics company operating globally. It is focused on research and development on diagnostics and therapeutics in the field of microRNAs. The firm markets and sells four diagnostic tests based on its microRNA technologies namely, RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer, mi-LUNG, mi-KIDNEY which is a microRNA-based kidney tumor classification test for pathology samples and RosettaGx Reveal which is a microRNA-based assay for the diagnosis of indeterminate thyroid fine-needle aspirate samples. Its revenues include Clinical testing revenues and Licensing revenues, of which Clinical testing revenue is maximum. The group generates its revenues mainly from diagnosing patient tissue.

Top Ranked Articles about Rosetta Genomics Ltd

Dec. 22 Forum Update: 'Merry Christmas' Edition A summary of value investing forum activity for December
Ahead of Christmas, GuruFocus users shared good value investing insights on our Forum, including comments about mergers, acquisitions and Warren Buffett (Trades, Portfolio)’s market indicator. Read more...

Ratios

vs
industry
vs
history

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history

More Statistics

Revenue (TTM) (Mil) $5.49
EPS (TTM) $ -7.75
Beta0.86
Volatility55.58%
52-Week Range $0.23 - 2.82
Shares Outstanding (Mil)5.93

Analyst Estimate

Dec17
Revenue (Mil $)
EBIT (Mil $)
EBITDA (Mil $)
EPS ($) -5.50
EPS without NRI ($) -5.50
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: ----
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAN
Lower Leverage yoyN
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}